Clobetasol

證據等級: L5

預測適應症: 1 個

Clobetasol: From Inflammatory Skin Conditions to Primary Cutaneous T-Cell Lymphoma

One-Sentence Summary

Clobetasol propionate is a superpotent topical corticosteroid classically used to manage severe inflammatory skin conditions such as psoriasis and eczema. The TxGNN model predicts it may be effective for primary cutaneous T-cell lymphoma (CTCL)—most notably early-stage mycosis fungoides (MF)—with no registered clinical trials but 20 publications in the literature currently supporting this direction. Real-world observational data and single-institution clinical series indicate a response rate exceeding 90% in patch-stage MF, lending substantial biological plausibility to the model’s prediction.

Quick Overview

Item	Content
Original Indication	Inflammatory skin conditions (psoriasis, eczema, and other corticosteroid-responsive dermatoses)
Predicted New Indication	Primary Cutaneous T-Cell Lymphoma (CTCL / Mycosis Fungoides)
TxGNN Prediction Score	99.51%
Evidence Level	L3
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why Is This Prediction Reasonable?

Clobetasol propionate is a Class I (superpotent) topical glucocorticoid. Its anti-neoplastic activity in CTCL is not coincidental—glucocorticoids bind the intracellular glucocorticoid receptor (GR), which in turn induces apoptosis selectively in malignant T-lymphocytes via GR-mediated transcriptional reprogramming. Simultaneously, clobetasol suppresses the tumor-permissive microenvironment by inhibiting pro-inflammatory cytokines (IL-2, IFN-γ, TNF-α) and downregulating the NF-κB survival pathway. This dual mechanism—direct cytotoxicity plus immune microenvironment modulation—is mechanistically distinct from, yet complementary to, conventional CTCL agents such as retinoids or nitrogen mustard.

Early-stage MF (patch/plaque stage) is characterized by malignant CD4+ T-cells confined to the epidermis and superficial dermis. This is the anatomical zone where a superpotent topical corticosteroid reaches therapeutic concentrations, making the route of administration pharmacologically rational. Furthermore, clobetasol has demonstrated selective apoptosis-inducing capacity specifically for CD4+ T-cell subpopulations, which aligns precisely with the CD4+ immunophenotype that defines the majority of CTCL cases.

From a clinical standpoint, the prediction is strongly supported by existing practice: the University of California, San Francisco (UCSF) has listed topical clobetasol as its first-line treatment for patch-stage MF in a series of approximately 200 patients, reporting response rates exceeding 90%. A 2020 observational study and a 2025 head-to-head comparison with bexarotene further corroborate efficacy. Taken together, the mechanistic, pharmacokinetic, and clinical lines of evidence converge coherently, explaining why TxGNN assigns a near-perfect prediction score.

Clinical Trial Evidence

Currently no related clinical trials registered for Clobetasol in primary cutaneous T-cell lymphoma.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39741016	2025	Comparative Study	Anais brasileiros de dermatologia	Head-to-head comparison of clobetasol propionate vs. bexarotene in early-stage MF; one of the first studies directly pitting topical steroid against a retinoid
32603400	2020	Retrospective Observational Study	Cutis	Evaluated cutaneous adverse effects of clobetasol propionate 0.05% cream in early-stage MF; confirmed high efficacy with minor side effects despite prolonged use
14686970	2003	Clinical Review / Case Series	Dermatologic Therapy	UCSF experience in ~200 patients: topical high-potency corticosteroids yielded >90% response rate in patch-stage MF; clobetasol designated first-line therapy
25027222	2014	Case Report	Nederlands Tijdschrift voor Geneeskunde	9-year-old girl with hypopigmented MF (rare pediatric CTCL subtype) successfully treated with clobetasol 0.05% ointment 4 days per week
28031140	2016	Case Series / Retrospective	Skinmed	Patient initially treated with topical clobetasol before CTCL (angioimmunoblastic T-cell lymphoma) was confirmed; illustrates diagnostic overlap and use pattern
36846176	2023	Case Report & Literature Review	Clinical Case Reports	MF mimicking psoriasis: topical steroids prescribed before MF diagnosis established, highlighting the diagnostic challenge and real-world corticosteroid exposure
30677799	2018	Review	Dermatology Online Journal	Overview of lymphomatoid papulosis (LyP) as low-grade CTCL variant; discusses monitoring vs. treatment approach per current consensus guidelines
17083888	2006	Review	Dermatology Online Journal	Diagnostic and therapeutic algorithm for primary cutaneous CD30+ anaplastic large T-cell lymphoma, an indolent CTCL subtype; contextualizes the CTCL disease spectrum
33026773	2020	Case Report	Journal of Drugs in Dermatology	Persistent agminated CD30+ lymphoproliferative disorder (LyP); documents treatment modalities used across the CTCL spectrum
39803735	2024	Case Report	Acta Dermatovenerologica Croatica	Ultra-high-frequency ultrasound used to objectively assess chlormethine gel (an alternative topical therapy) efficacy in MF; provides comparative context for topical treatment evaluation methodology

Philippines Market Information

Clobetasol propionate currently has no registered product licenses with the FDA Philippines. The drug is not marketed in the Philippines as of the data cutoff date (2026-04-04).

Any clinical use would require importation through a Special Access Scheme or compassionate use pathway under Philippine FDA regulations.

Safety Considerations

Detailed TFDA package insert warnings and contraindications were not available at the time of this report (Data Gap: DG001). Drug–drug interaction data was also not retrievable from the queried database.

Please refer to the originator package insert (e.g., Temovate® or equivalent) and the Philippine FDA guidance for full safety information, including class-effect warnings applicable to superpotent topical corticosteroids (e.g., HPA axis suppression, skin atrophy, local adverse effects with prolonged use).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Topical clobetasol propionate has substantial real-world evidence supporting its use in early-stage mycosis fungoides (the most common form of primary CTCL), with observational data reporting response rates >90% and a favorable safety profile under supervised use. While no formal randomized controlled trials have been registered, the mechanistic rationale is sound, clinical practice at major academic centers already employs clobetasol as first-line therapy, and the 2025 comparative study further strengthens the evidence base. The absence of Philippine market registration is the principal logistical barrier.

To proceed, the following is needed:

Regulatory pathway: Identify a Special Access or compassionate use route through the FDA Philippines for product importation
Safety documentation: Obtain and review the full TFDA or originator package insert (including HPA axis suppression risks, skin atrophy, and ocular adverse effects) to complete the S1 safety assessment (Data Gap DG001)
MOA verification: Confirm DrugBank mechanism of action data (Data Gap DG002) to formally document GR-mediated apoptosis as the repurposing rationale
Indication scoping: Define the specific CTCL subtype and disease stage (early patch/plaque-stage MF recommended based on evidence), treatment duration protocol, and monitoring schedule (skin response assessment, HPA axis function)
Prospective registry or study: Given the absence of registered clinical trials, consider initiating a prospective patient registry or a small pilot study in collaboration with a dermatology/oncology center in the Philippines to generate local evidence
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.